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To all of you who have suffered a hip fracture.  
The effort to improve treatment and care continues.   
      
      
      
      
      
      
      
      
      
      
      
  
  
ABSTRACT 
 
Hip fracture in the elderly is a serious condition associated with increased mortality. 
Survivors experience an increase in morbidity and disability that affect their independence 
and quality of life; the outcome for patients with dementia is particularly poor. Many hip 
fracture patients have signs of malnutrition already on admission and this patient group has 
been shown to have a lower body mass index (BMI) than aged-matched controls. A catabolic 
state develops following hip fracture, characterized by loss of bone mineral density (BMD) 
and muscle mass. The combination of generalized loss of muscle mass, muscle strength 
and/or physical performance is known as sarcopenia, which impacts functionality and health-
related quality of life. This thesis has three major aims: 1) to study the possible association 
between BMI, a potentially modifiable factor, and one-year mortality, as well as the ability to 
return to independent living following hip fracture; 2) to evaluate the effect of nutritional 
supplementation on bone mineral density (BMD), body composition, muscle strength and 
health-related quality of life (HRQoL) following hip fracture; and 3) to investigate factors of 
importance for preservation of ambulatory function and activities of daily living (ADL) 
following hip fracture in patients with cognitive impairment.  
 
Study I A prospective study of 843 elderly patients with hip fracture, without severe 
cognitive impairment, who came from an independent living situation at the time of 
admission. The results show that overweight was associated with increased one-year survival 
and a greater likelihood of independent living one year post-fracture.  
Study II A randomized controlled study in which 79 patients with hip fracture were 
randomized to one of three treatment groups. Six months of postoperative treatment with 
protein and energy-rich supplementation combined with orally administered bisphosphonate, 
calcium and vitamin D were shown to have a small additive effect on bone mineral density 
compared with bisphosphonate and calcium alone.  
 
Study III A randomized controlled study of the same population as in study II. Postoperative 
treatment with protein and energy-rich supplementation did not prevent loss of lean mass 
following hip fracture. However, trends toward improved handgrip strength and HRQoL 
were observed following nutritional supplementation.  
 
Study IV A prospective study of 246 patients with femoral neck fracture and cognitive 
impairment, but ambulant prior to fracture. In addition to ambulatory and ADL function prior 
to fracture, the results showed that discharge to rehabilitation facilities was associated with 
preserved ambulatory function and ADL skills at the 4-and 12 month follow-ups. 
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1 BACKGROUND 
  
1.1 HIP FRACTURE 
1.1.1 Definition, anatomical classification and surgical treatment 
Hip fracture is the general term for fractures located in the proximal part of the femur. The 
two most common types of hip fracture are those found in the femoral neck and in the 
trochanteric region, which account for about 51% and 38%, of hip fractures, respectively. The 
remainder comprise subtrochanteric and basocervical fractures 
1
. In femoral neck fractures, 
surgical treatments generally include internal fixation with two screws or hip replacement. 
Trochanteric and subtrochanteric fractures are treated with dynamic hip screws or medullary 
nailing. 
 
1.1.2 Epidemiology 
In Sweden, with a population of 9.7 million, about 70 000 osteoporosis-related fractures 
occur each year and 26% of these are hip fractures 
2
. Hip fractures are most common among 
the elderly, with a greater proportion of women (68%) 
1
. The average age at fracture has been 
reported to be 83.8 years for women and 82.1 years for men 
3
. Hip fractures in this age group 
usually occur indoors through low-energy impact such as a fall on the floor 
4
. Hip fractures in 
the elderly population are serious because they often result in long-term functional 
impairment and loss of independence. Morbidity is high 
5,6
, and the mortality rate has been 
reported to be 3 to 5 times higher in women and 5 to 7 times higher in men during the first 
year after surgery 
7,8
. Advanced age, male sex, poor general health and cognitive dysfunction 
are factors known to increase the mortality rate 
9,
 
10-12
. 
 
 
1.1.3 Osteoporosis 
Osteoporosis is characterized by low bone mass, expressed as bone mineral density (BMD). 
BMD is a mathematical ratio of the measured mineral content in a defined area of bone 
13
. In 
addition to low BMD, osteoporosis is characterized by micro-architectural deterioration of 
bone tissue, leading to increased bone fragility and risk of fractures. The most validated 
technique to measure BMD is by dual energy X-ray absorptiometry (DXA). Based on 
measurement of BMD, osteoporosis is defined as a T-score of - 2.5 standard deviations (SD) 
below the average value for healthy young, women 
14
. A normal BMD is defined as a T-score 
higher than -1 SD compared with the reference population. BMD decreases with age after 
reaching its peak between ages 20-30. The rate of bone loss accelerates in women during 
menopause. However, differences in the rate of bone loss between men and women decrease 
by age 65 
15
. Non-modifiable risk factors for osteoporosis include age, female sex and early 
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menopause (<47 years), as well as history of fracture, steroid treatment, ethnicity and family 
history. 
However, there are also well known risk and lifestyle factors that can be influenced such as 
smoking, alcohol, a propensity to fall and low sun exposure 
16
. In addition, underweight and 
poor nutritional status are potentially modifiable risk factors for osteoporosis and fracture. 
 
 
1.1.4 Nutritional status, body mass index and biochemical markers of 
nutrition. 
Optimal nutritional status entails stable weight with balanced energy intake and nitrogen 
production. Disruption of this balance will result in weight gain or loss. The general pattern 
of weight change over the course of life is weight gain up to approximately age 60 followed 
by weight loss. Body composition changes throughout life, but a slow increase of fat with age 
during adulthood has been described, though with great variability between individuals and 
the sexes 
15
. Skeletal muscle mass is relatively stable until age 30 to 40, after which it begins 
to decrease with accelerated loss accompanying older age; the rate of loss is reported to be 
greater for leg muscle than for arm muscle 
17
. Weight loss of 10% or more in the elderly is 
associated with a large risk of malnutrition 
18
. One commonly used anthropometric marker of 
nutritional status is body mass index (BMI, kg/m²). This index is used to classify underweight 
(< 18.5), normal weight (18.5-25 kg/m²), overweight > 25 and obesity (≥ 30 kg/m²). The BMI 
ranges are set by the World Health Organization (WHO) to predict the impact of body weight 
on morbidity and mortality in young and middle-aged adults 
19
. The European Society for 
Clinical Nutrition and Metabolism (ESPEN) has adjusted the threshold for people above age 
65 and declared that a BMI of less than 20 is to be regarded as underweight or at risk of 
undernutrition 
20
. The corresponding figure for people older than age 70, as set by the 
Swedish National Board of Health and Welfare, is a BMI of less than 22, which together with 
weight loss of 10% or more is defined as being malnourished 
21
. A low BMI has been 
reported to be more common among patients with hip fracture compared with age-matched 
controls 
22,
 
23
, and a BMI of less than 22 kg/m² was found in about 25% of one hip fracture 
population 
24
. A recent study showed that the prevalence of malnourishment among hip 
fracture patients was nearly 38% 
25
, while others have reported it to be between 15 and 33% 
26,
 
24
. Despite changes in care through the years, many patients with hip fracture are still 
identified as being underweight based on their BMI. The association between BMI and 
outcome following hip fracture has not been fully explored. 
 
Serum insulin-like growth hormone-I  
Although an ideal biochemical marker for malnutrition does not exist, serum insulin-like 
growth hormone (IGF-I) may reflect nutritional status and IGF-I is known to respond to 
nutritional support 
27
. IGF-I is a peptide hormone with anabolic effects on protein and 
carbohydrate metabolism, exerted through increased uptake of amino acids, thereby making it 
 3 
 
an important regulator of muscle mass 
28
. Bone has also been shown to be another target for 
IGF-I 
29
. IGF-I levels decrease in malnourished patients and increase in response to 
nutritional support 
28
. IGF-I is mainly synthesized in the liver and production is regulated by 
growth hormone, gonadal steroids, thyroxine, cortisol, nutrition and genetic factors. The 
bioactive component accounts for less than 1% and the major proportion is bound to IGF 
binding proteins 
30
 Circulating IGF levels reach a maximum during peripubertal growth and 
gradually decline with age 
31,
 
32
. The systemic actions of IGF-I are affected by metabolic 
disorders such as GH deficiency, acromegaly, obesity and diabetes 
30
. IGF-I is also affected 
by trauma associated with hip fracture and a marked reduction has been reported after 
surgery
33
. 
 
Serum albumin 
Serum levels of albumin may be subnormal in malnutrition 
30
. However, as is true of all 
protein markers, levels must be interpreted with caution since they may be affected by several 
factors such as hydration status, liver function and especially by the acute phase response 
seen after hip fracture. Nevertheless, they are used to monitor nutritional support as a 
complement to other nutritional assessments 
30
.  
 
1.1.5 Marker of bone resorption 
C-terminal telopeptide of collagen-I (CTX-I) 
Bone turnover is a continuous process of bone resorption and formation that occurs in 
localized areas known as bone remodeling units. Serum CTX-I, as a collagen degradation 
product, is one of the biochemical markers of bone resorption 
34
 that has been recommended 
for use in clinical practice and in research studies by the International Osteoporosis 
Foundation 
35
. Serum levels of CTX exhibit diurnal variation with the highest values at night 
and the lowest in the afternoon. Other causes of variability are age, sex and a number of 
diseases, including primary hyperparathyroidism, Paget’s disease, myeloma and chronic 
kidney disease. Following fracture and during fracture healing, serum CTX-I levels increase 
within two weeks and then remain elevated for up to one year compared with pre-fracture 
levels 
36,
 
37
. Treatment with antiresorptive drugs such as bisphosphonates decreases CTX-I 
levels, which can therefore be used to monitor treatment compliance 
35
. 
 
 
1.1.6 Sarcopenia  
A decline in skeletal muscle mass is associated with the aging process 
15
. Loss of muscle 
mass has been reported to be 1-2% yearly after age 50 
38
. After a hip fracture, the trauma 
itself, presurgical fasting and hip fracture-associated immobilization contribute to loss of 
muscle mass and strength. As much as 5-6% of muscle mass has been reported to be lost 
during the first year following fracture 
39,40
. The current definition of sarcopenia is a 
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combination of reduced muscle mass and muscle function (strength or physical performance) 
41,
 
42
. Sarcopenia is associated with an increased risk of falls 
43
, and an impaired ability to 
remain independent in activities of daily living (ADL) 
44
. Increased muscle wasting following 
hip fracture is likely to be one of several factors that influence poor outcomes such as 
impaired walking ability, ADL function 
5
, and deterioration in health-related quality of life 
(HRQoL) according to EuroQoL (EQ-5D) 
45
. Sarcopenia is complex and the underlying 
mechanisms are multifactorial, including both morphological and functional changes in 
muscles. Factors that contribute to these changes include reduced physical activity, poor 
nutritional intake, genetic factors, inflammatory activity and a decrease in anabolic hormones 
46
. The prevalence of low muscle mass measured by DXA has been reported at 20-85% in hip 
fracture patients, depending on age and sex 
47,
 
48
. Studies on muscle mass together with 
muscle strength following hip fracture are lacking. Hand grip strength (HGS) as measured by 
a hand dynamometer is one method to assess muscle strength 
41
. A strong association has 
been shown between HGS and leg muscle strength; HGS has also been shown to predict 
mobility better than muscle mass 
49
. 
 
 
1.1.7 Nutritional supplementation, oral bisphosphonate and vitamin D 
In order to maintain muscle mass in elderly there are recommendations for a higher daily 
protein intake, both in healthy individuals and in those who have acute or chronic diseases 
50
. 
Voluntary food intake is often insufficient to meet the elevated protein and energy 
requirements following hip fracture surgery 
26
. Oral nutritional supplements are 
recommended for elderly hip fracture patients 
20
. One study showed that postoperative protein 
supplementation reduces proximal femur bone loss one year post-hip fracture 
51
. A reduced 
postoperative complication rate 
52
, and a shorter length of hospital stay have also been shown 
by protein-rich oral nutritional supplementation 
53
. However, the benefit of nutritional 
supplementation for hip fracture patients has not been conclusively demonstrated, as stated in 
a Cochrane Collaboration review 
54
 and few studies have been carried out concerning 
nutritional effects on bone mineral density and body composition as measured by DXA. 
 
Adequate serum levels of calcium and vitamin D are important for bone metabolism, but this 
combination alone is not recommended for the treatment of osteoporosis due to the lack of 
evidence to support their ability to reduce fracture risk 
55
. Vitamin D3 (cholecalciferol) has 
been reported to have preventive effects on falls 
56
, while vitamin D2 (ergocalciferol) has 
been shown to have a beneficial effect on muscle strength in older women with insufficient 
levels of serum-25OH-vitamin D 
57
. Bisphosphonates reduce bone resorption and are widely 
used for primary and secondary prevention of osteoporotic fractures 
58,59,60, 61,62
. An increase 
in total hip BMD has been reported after treatment with bisphosphonates in patients with a 
recent hip fracture 
63
. 
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1.1.8 Rehabilitation and cognitive impairment 
Previous reviews describe strong evidence for the benefits of exercise programs for outcome 
regarding functional recovery, balance and muscle strength following hip fracture 
64,
 
65
. 
Multidisciplinary rehabilitation following hip fracture has also been shown to improve 
outcome regarding mobility and ADL 
66
. The prevalence of dementia or severe cognitive 
impairment has been reported in about 15 to 32% of hip fracture patients 
67, 68
; a rough 
assessment of cognition can be made with the Short Portable Mental Questionnaire 
(SPMSQ)
69
. It has been shown that the presence of any kind of severe cognitive impairment, 
including delirium, detected during hospital stay, is a risk factor for poor outcome after hip 
fracture with influence on ADL, ambulatory capacity and mortality 
11,
 
70, 71
. However, the 
presence of dementia does not preclude the restoration of baseline function following hip 
fracture 
72
. Despite this knowledge are patients with dementia less likely to have the same 
training opportunities as cognitively intact individuals 
5
. Preserved ambulatory function is 
one of several factors associated with health-related quality of life after hip fracture 
45
 and it 
is therefore important to identify factors that help to preserve this function. 
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2 AIMS 
 
Study I 
The primary aim was to investigate the association between body mass index and one-year 
mortality, while the secondary aim was to study the association between BMI and 
independent living one year postoperatively. 
 
Study II 
To evaluate the effect of postoperative treatment with calcium, vitamin D and 
bisphosphonate, alone or together with protein-rich nutritional supplementation, on total hip 
and total body BMD. 
 
Study III 
To evaluate the combined effects of protein-rich nutritional supplementation and 
bisphosphonate on body composition, handgrip strength and HRQoL. 
 
Study IV 
To explore factors associated with preservation of ambulatory function and ADL skills at 4 
and 12 months postoperatively in patients with femoral neck fracture and cognitive 
impairment. 
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3 METHODS 
 
3.1 PATIENTS, SETTINGS AND DESIGN 
 
Charts of included patients in studies I-IV are shown below (Figure 1 and 2).   
 
Figure 1 Chart of included patients studies I and IV 
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Figure 2 Chart of included patients studies II and III 
 
 
 
Abbreviations: BN/N: bisphosphonate together with nutritional supplementation and 
calcium + vitamin D; B: bisphosphonate and calcium + vitamin D; C: controls treated with 
calcium + vitamin D 
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Study I 
The population in this prospective study was derived from a Stockholm Hip Fracture Group 
Study and consisted of 843 patients with hip fracture (femoral neck, trochanteric or 
subtrochanteric), who were admitted to one of four University hospitals in Stockholm 
(Karolinska University Hospital, Huddinge; Karolinska University Hospital, Solna; Danderyd 
Hospital; and Stockholm South Hospital) during one year. Inclusion criteria were age >65 
years, living independently and no diagnosis of dementia or severe cognitive impairment 
according to the Short Portable Mental Questionnaire (SPMSQ ≥3 correct answers). 
 
 
Studies II and III 
These studies built on a randomized, controlled, interventional trial in which the population 
used for study II and study III was the same and included 79 men and women with hip 
fracture (femoral neck or trochanteric) admitted to any of the four university hospitals in 
Stockholm, Sweden during 2005-2009. Study II focused on the outcome of bone mineral 
density and study III on body composition, handgrip strength and HRQoL. Inclusion criteria 
were: age ≥60 years, no severe cognitive impairment (SPMSQ ≥3), ambulatory prior to 
fracture, and body mass index (BMI) ≤28 kg/m2. Exclusion criteria were: treatment with 
bisphosphonate within the last year and pathological fracture, or patients with bone metabolic 
disorders such as primary hyperparathyroidism, osteogenesis imperfecta, Paget’s disease or 
myeloma. Also excluded were patients with abnormal hepatic or renal laboratory parameters 
such as S-ALT, S-AST ≥ twice the normal reference range respectively, S-creatinine >130 
µg/L or GFR <30 ml/min. Additional exclusion criteria were lactose intolerance, dysphagia, 
esophagitis, gastric ulcer or malignancy, diabetes mellitus associated with nephropathy or 
retinopathy, active iritis or uveitis, as well as patients with alcohol/drug abuse or overt 
psychiatric disorders. 
 
Intervention studies II and III 
Patients were randomized into three groups using sealed envelopes in blocks of 12. All 
patients received calcium (1000 mg) and vitamin D3 (800 IE) daily. The first group was 
randomized to treatment with bisphosphonates, risedronate 35 mg (Optinate® Septimum) 
once weekly for 12 months (n=28). The second group was treated with bisphosphonates 
along with daily nutritional supplementation (Fresubin® protein energy drink) for the first six 
months (n=26). The third group served as controls (n=25) and was treated with calcium and 
vitamin D alone (Calcichew-D3®) for 12 months. The nutritional supplement was a liquid 
formula and contained 150 kcal and 10 grams protein/100 ml with a balanced mix of 
micronutrients. The protein content was milk-based consisting of 80% casein and 20% whey. 
Patients were prescribed 200 ml twice daily of the liquid supplement. 
 
Pharmacological treatment and nutritional supplementation began as soon as patients were 
stable from a cardiovascular standpoint, able to take food by mouth and able to sit in an 
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upright position for one hour after taking their tablets. The research nurses interviewed 
patients by telephone regarding compliance, food intake, pain and general state of health. 
 
 
Study IV 
This was a prospective study of 246 patients aged > 65 years, with femoral neck fracture who 
were admitted to one of four university hospitals in Stockholm during one year. Included 
were patients with a diagnosis of dementia or severe cognitive impairment (SPMSQ 0 to 2 
points), who were ambulatory prior to fracture.  
 
 
3.2 DATA COLLECTION 
 
Study I 
Upon hospital admission hip fractures were classified by orthopedic surgeons, while 
anesthesiologists carried out a separate classification based on the American Society of 
Anesthesiologists (ASA) classification system 
73
 prior to surgery. At inclusion, patient data 
were recorded, including age, sex, type of fracture and surgical method, as well as pre-
fracture Katz ADL index 
74
, use of walking aids and living situation. Research nurses 
assessed cognitive status according to the Short Portable Mental Status Questionnaire 
(SPMSQ) 
69
. Weight measurements were obtained either using a bed scale on admission or 
postoperatively on a wheelchair scale. Height was measured in supine position. Body mass 
index (BMI) was calculated (kg/m²). BMI levels in relation to one-year survival were 
analyzed from the lowest value to the highest value and based on these results (see below), 
patients were categorized into three different BMI groups: BMI <22, 22-26, and ≥26. BMI 
<22 was used as a cut-off for underweight and risk of malnutrition as suggested by the 
Swedish National Board of Health and Welfare. The upper limit, BMI >26, was chosen after 
analysis of how various BMI levels relate to one-year survival. The middle group comprised 
patients with BMI 22-26, representing those between the lowest and highest cut-off values 
described above.  
 
Follow-up study I 
Patients were followed up at 12 months. Information on living condition was obtained by 
telephone interviews but also by using mailed questionnaires or by outpatient´s visits if 
needed because of reported problems from the hip. Mortality during the first year after the 
fracture was obtained from the hospital discharge register and the Swedish population 
records. 
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Study II 
A total body BMD as well as a total hip BMD on the uninjured hip were obtained in the 
immediate postoperative period by DXA measurements. Height and weight were measured as 
described in study III and BMI was monitored. The biochemical parameters considered in 
study II were plasma-calcium (mmol/L), plasma-albumin (g/L) and serum-PTH (ng/L), 
which were analyzed according to standard hospital laboratory procedure for each center. 
Serum-25OHD (nmol/L) was analyzed at baseline and again after 12 months using 
chemiluminescence immunoassays (LIASON® 25OH vitamin D TOTAL Assay, DiaSorin 
Inc. Stillwater, MN, USA). To evaluate changes in bone turnover, serum-CTX-I (ng/L) was 
analyzed at baseline and at 12 months using the Beta-CrossLaps assay (Roche diagnostics 
GmbH, Mannheim, Germany), a 2-site immunometric (sandwich) assay based on electro-
chemiluminescence detection. The interassay coefficient of variation (CV) was < 20%. 
 
 
Study III 
Fat mass (FM), lean mass (LM) and bone mineral content (BMC) were measured by DXA 
and expressed in kilograms (kg). Weight was calculated from the sum of LM, FM and BMC, 
obtained from the DXA measurements and defined as total body mass (kg); height was 
measured in supine position. ASA score, handgrip strength and HRQoL (EQ-5D) were 
assessed. Biochemical measures considered relevant to this study were analyzed. To serve as 
a nutritional biochemical marker, we analyzed serum levels of insulin-like growth factor-I (S-
IGF-I, µg/L) by radioimmunoassay 
75
, and also used these levels to express an age-adjusted 
SD score; a score within 2 SD was considered within the age reference range 
76,
 
77
.   
 
Follow-up studies II and III 
In order to compare baseline results, DXA measurements of body composition, total hip and 
total body BMD were obtained at the 6 and 12 month follow-up visits, along with assessment 
of weight, handgrip strength and quality of life. Biochemical measurements were also 
analyzed at 6 and 12 months, except for serum CTX-I and serum 25OHD, which were 
analyzed only at the 12 month follow-up visit to compare with baseline. 
 
 
Study IV 
For this study we recorded age, sex, fracture type and number of comorbidities, as well as 
ASA and SPMSQ scores at inclusion. Surgical method, postoperative complications, and 
discharge to rehabilitation unit were also recorded. Due to the presence of dementia or severe 
cognitive impairment, information was obtained through proxy interviews with respect to 
living situation, ambulatory function, reliance on walking aids and ADL skills.  
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Follow-up study IV 
Patients were followed up at 4 and 12 months regarding the above-mentioned variables. 
Information at the two follow-ups was primarily obtained by telephone interviews, as well as 
by mailed questionnaires or outpatient visits if necessary due to hip-related problems. In 
addition, information concerning healing complications, reoperation and mortality were 
obtained from hospital records. Ambulatory function at the two follow-ups was compared 
with ambulatory function on admission and if unchanged was referred to as “preserved” 
ambulatory function. Similarly, ADL index at the follow-ups was compared with ADL index 
on admission. 
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3.3 ASSESSMENT OF MOBILITY AND LIVING CONDITIONS 
 
Ambulatory function was defined as: 1) ability to walk outdoors 2) ability to walk only 
indoors or 3) inability to walk. 
Reliance on walking aid was defined as: 1) No aids or one cane; 2) walker or two canes; 3) 
wheelchair. 
Patients admitted from their own home or service flats were defined as living independently 
and patients living in a nursing home or residential care facility were classified as 
institutionalized. Patient data also included whether they shared a household or lived alone. 
 
3.4 DESCRIPTION OF INSTRUMENTAL ASSESSMENTS 
 
 
American Society of Anesthesiologists (ASA) 
A classification system used to assess a patient’s physical status prior to anesthesia and 
surgery 
73
. ASA 1 represents a completely healthy person, ASA 2 pertains to mild systemic 
disease, ASA 3 signifies a severe systemic disease that is incapacitating, ASA 4 reflects 
severe disease that is both incapacitating and a constant threat to life, while ASA 5 signifies a 
moribund person who is not expected to survive 24 hours with or without surgery. This 
grading system has been used as a comorbidity index and has been shown to predict mortality 
in hip fracture patients 
78
. Patients scoring 3 or 4 are at higher risk of having complications 
compared with those in ASA class 2 
79
.  
In studies I and III patient were categorized as ASA 1-2 and ASA 3-4. In study IV patients 
were categorized as ASA 1-2, ASA 3 and ASA 4-5. 
 
 
Activities of daily living (ADL) 
The Katz ADL index describes the degree of independence/dependence in six basic activities 
of daily living (bathing, dressing, going to the toilet, transferring, continence, feeding) and 
was developed by Katz et al. 
74
. ADL index A refers to independence in all six activities; B, 
dependence in one activity; C, dependence in bathing and one additional activity; D, 
dependence in bathing, dressing and one additional activity; E, dependence in bathing, 
dressing, going to the toilet and one additional activity; F, dependence in bathing, dressing, 
going to the toilet, transferring and one additional activity; G, dependence in all activities. 
The Katz ADL index was used in studies I, III and IV. Patients were categorized into ADL 
index A-B or C-G. 
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Short Portable Mental Status Questionnaire (SPMSQ) 
SPMSQ is a 10-item test, used to detect the presence of cognitive dysfunction and has shown 
good test-retest reliability 
69
. It has been validated with similar rates of sensitivity and 
specificity to that of the Mini mental State Examination (MMSE), which is the most widely 
used screening test for the assessment of cognitive dysfunction 
80,
 
81
. In comparison with the 
MMSE, the SPMSQ is easily administered to bedridden patients, as in the case of hip 
fracture, since it does not include writing exercises, which can be difficult to perform in 
supine position. Questions include orientation to time, place, memory, current event 
information and calculations. The number of errors are counted and low scores (0-2 correct 
answers) indicate severe cognitive impairment, 3-7 mild to moderate cognitive impairment,  
while 8 to 10 correct answers are considered as having intact cognitive function.  
Only patients without severe cognitive impairment (≥ 3 correct answers) were included in 
studies I, II and III. Study IV included patients with severe cognitive impairment (diagnosis 
of dementia and/or SPMSQ score of 0-2 points). 
 
 
Health-related quality of life (HRQoL) according to EuroQol (EQ-5D) 
EuroQoL is a standardized self-rating scale for health status containing five items (mobility, 
hygiene, activities, pain/discomfort and anxiety/depression), each with three levels of 
responses 
82
; no problems, some problems or major problems. The items are compiled into a 
health index according to a mathematical formula 
82
. An EQ-5D index of 0.00 indicate the 
worst possible health state and a value of 1.00 full health 
82
. EQ-5D has been used to describe 
HRQoL in a general Swedish population 
83
, and has shown good responsiveness in elderly 
patients with femoral neck fractures 
84
.  
 
The EQ-5D index was used in study III for assessment of health-related quality of life. 
 
JAMAR hand dynamometer 
Isometric muscle strength (kg) can be measured with a hand dynamometer. Hand grip 
strength (HGS) by the JAMAR dynamometer used in study III has previously shown good 
reproducibility (r >0.80) and reliability (r =0.98) 
85,
 
86
. This measurement was performed with 
the patient sitting in a chair with a back support, forearms resting on the arms of the chair and 
wrists protruding just over the end. The highest value in the dominant hand from three tries 
was recorded 
87
. Cut-off values used for low HGS were <30 kg in men and <20 kg in women 
41
.  
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Dual energy X-ray absorptiometry (DXA) 
For clinical use, DXA provides the most accurate measure to calculate body composition 
including lean mass, fat mass and bone mineral content 
15
. The DXA measurement is based 
on x-rays at two different energy levels. A detector measures the amount of energy absorbed 
or passing through the examined body part and is mathematically related to the density of 
tissues under measurement. Since the two energy levels are absorbed differently by soft tissue 
and bone, it is possible to distinguish between them. Radiation exposure is much lower than 
in chest x-ray 
15
 and measurement can be quickly performed. 
 
 
Bone mineral density measured by DXA 
BMD and body composition were measured using either Hologic (Hologic, Inc. Waltham, 
MA, USA) or GE Lunar (Madison, WI, USA) densitometers. The DXA image is two-
dimensional and BMD was expressed as areal density, grams per square centimeter (g/cm²), 
and as standard deviation in relation to both mean value among healthy young individuals (T-
score) and mean value of age-and sex-matched adults (Z score). To compensate for variation 
in BMD measurements among different centers and densitometers, equations to standardize 
bone mineral density were used to create sBMD in mg/cm² for the total hip results 
88
. To 
calculate changes in BMD, the areal BMD (g/cm²) was used 
13
. Since patient position is 
important when comparing repeated total hip measurements, a device to stabilize leg rotation 
was used. Baseline and follow-up images were compared regarding region of interest (ROI). 
The precision error (GE Lunar) of the BMD results was tested on 30 outpatients on two 
occasions according to International Society for Clinical Densitometry (ISCD) guidelines 
89
 
and showed 0.010 g/cm² for the total hip and 0.007 g/cm² total body BMD, respectively.  
 
 
Body composition measured by DXA 
DXA measurements of body composition represent a 3-compartment model that includes fat 
mass (FM), bone mineral content (BMC) and lean mass (LM). Lean mass is composed of 
muscle, visceral organs and water. The sum of LM and BMC represents fat-free mass (FFM). 
To normalize for body size, FFM and FM were divided by height squared to calculate fat-free 
mass index (FFMI, kg/m²) and fat mass index (FMI, kg/m²) 
90
. Cut-offs for low FFMI were 
<17 kg/m² for men and <15 kg/m² for women 
91
, based on reference values for body 
composition in a Swiss population 
91
. Thus, a FFMI lower than the 10th percentile of the 
reference population was considered to be low 
91,
 
90
. Data on lean mass from DXA 
measurements of legs and arms were used to calculate appendicular skeletal muscle mass 
(kg) 
92
. The lean mass of the un-fractured leg multiplied by 2 was used at baseline to avoid 
overestimation in the fractured leg due to postoperative edema 
47
. An appendicular lean mass 
index (aLM, kg/m²) was calculated by dividing appendicular lean mass (aLM, kg) by height 
squared 
92
. Cut-off points used for low aLMI were ≤7.23 kg/m² for men and ≤5.67 kg/m² for 
women 
93
. Reproducibility has been reported to be good for whole body DXA, LM (r =0.99) 
 17 
 
and FM (r =1.00) 
94
. Among several factors, reproducibility depends on accurate positioning 
of the patient 
94
. Hydration status when calculating fat-free mass is another potential source of 
error 
15
.  
 
 
3.5 STATISTICS 
IBM SPSS version 22.0 was the statistical software used in studies I, II and III; version 16.0 
for Windows (IBM, SPSS Statistics) was used for study IV. Mean, standard deviation, 
median, range and percentage were used in all four studies for descriptive purposes. The 
Student’s t-test was used to test for differences in normally distributed independent variables 
and the Kruskal-Wallis test was used to compare variables not normally distributed. In 
studies I and IV contingency tables were tested for differences using the Chi-square test. 
Fisher’s exact test was used for contingency tables when cells counts were expected to be less 
than 5. A p-value of < 0.05 was considered significant. 
 
Study I 
One-way analysis of variance (ANOVA) was used to test differences between groups 
regarding age. The association between the three BMI groups and one-year survival was 
evaluated using binary logistic regression analyses, both unadjusted and adjusted for age, sex 
and ASA score. The association between BMI groups and capacity for independent living 
following hip fracture were similarly analyzed and adjusted for age, sex, ASA score and 
shared household upon admission. 
 
Studies II and III 
Normal distribution of serum-CTX-I was achieved through transformation using a 
logarithmic scale. A paired samples t-test was used to compare intra-group differences in 
serum-CTX-I between baseline and 12-month follow-up. Non-parametric tests were used to 
analyze EQ-5D data. Univariate correlations between FFMI and aLMI, and between aLMI 
and HGS were analyzed using Pearson correlation coefficient and Spearman´s rank 
correlation coefficient, respectively. Differences between the three treatment groups were 
analyzed using covariance of analysis (ANCOVA). The ANCOVA analyses included 
exposure measures, treatment groups and sex as fixed factors. Age and baseline values for 
BMD, FFMI, FMI, serum-CTX-I, serum-25OHD and HGS were included as covariates. 
Baseline value was the only covariate used in the analysis of serum-PTH. Data were reported 
using complete-cases analysis and intention-to-treat (ITT) analysis. Missing data were 
processed for each of the outcome measures according to the hot-deck method 
95
, which 
replaces missing data with randomly assigned values taken from individuals stratified 
according to sex and age. ITT analyses were performed using the database with imputed data. 
Sample size in study II and III was based on lean mass.  
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Study IV 
In order to investigate associations with outcome pertaining to ambulatory function, ADL 
index and discharge to a rehabilitation facility, the following factors were included in a 
stepwise logistic regression analysis: age, sex, ASA score, number of comorbidities, 
ambulatory function before fracture, ADL index before fracture, type of fracture, surgical 
method, discharge to rehabilitation unit, living situation, major complications and 
reoperation. 
 
 
3.6 ETHICS 
 
Ethical considerations arise when data are collected on patients unable to provide consent due 
to cognitive impairment. Another ethical dilemma involves inclusion of frail patients in a 
vulnerable situation, such as after a hip fracture, which entails performing various 
measurements that may cause discomfort. However, inclusion of these frail patients in studies 
is of great importance for improving care and outcome. Patient discomfort must be weighed 
against the benefits of new knowledge and potential improvements in treatment. Another 
issue of concern in study II was that some patients who were defined as having osteoporosis 
were randomized to treatment with calcium and vitamin D alone, which is not evidence-based 
treatment for osteoporosis. However, at the time this study was carried out, calcium and 
vitamin D were regarded as basic treatment and patients with osteoporosis were offered 
follow-up in primary care after study completion. 
All studies were approved by the local ethics committee and were performed in accordance 
with the Helsinki Declaration 
96
. Participants provided written consent to participate in the 
studies. In patients with severe cognitive impairment written consent was obtained from a 
close relative or caregiver. 
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4 RESULTS 
 
4.1 STUDY I 
 
The average age of all study participants was 82 years (SD 7); 73% were women and mean 
BMI was 22.7 kg/m². Of 843 patients, 128 (15%) died during the first year after fracture. 
Mortality rate among men was 19% and among women 14% (p=0.06). The three BMI groups 
differed by age and sex, but not regarding fracture type, ASA score, ADL index, proportion 
living alone or reliance on walking aids. Mortality rates for those with a BMI of <22 and 22-
26 were 16% and18%, respectively, while the corresponding figure for those with BMI >26 
kg/m² was 6%. Both age and ASA score were found to be independently associated with one-
year mortality, while sex was not. Logistic regression analysis showed BMI to be 
independently related to one-year survival; odds ratio (OR) for the group with BMI >26 
kg/m² was 2.58 (CI 95%; 1.22-5.46), p=0.01 after adjustment for age, sex and ASA score.  
 
A total of 25% had not returned to independent living one year post-hip fracture. Remaining 
at institution were 28% of the patients with BMI <22 and 27% of the patients with BMI 22-
26, whereas the corresponding figure for patients with BMI >26 was 12%, (p=0.003).  
Significant factors related to independent living were age, ASA score and shared household, 
but not sex. Patients with BMI >26 were more likely to return to independent living 12 
months post-hip fracture; OR 2.62 (CI 95%; 1.37-5.02), p <0.01 after adjustment for age, sex, 
ASA score and shared household upon admission. There were no differences regarding 
mortality or independent living one year post-fracture among patients with BMI <22 kg/m² 
(cut-off for underweight in older adults), p=0.6, and among those with BMI 22-26 kg/m², 
p=0.95. 
 
4.2 STUDY II 
 
Seventy-nine patients were initially included in the study, of whom 67 were available at final 
follow-up. All patients were measured by DXA at inclusion; 68 were measured at 6 months 
and 66 at12 months. Because 9 patients had a total hip replacement on the uninjured side, 
their hip measurements could not be taken. The mean age of all included patients was 79 
years (SD 9); 56 (71%) were women. Other than reliance on walking aids, there were no 
significant differences between the three treatment groups. Complete-case analysis showed 
an increase in total hip BMD of 0.7% in the nutritional supplementation group (BN), whereas 
the bisphosphonate (B) and control (C) groups lost 1.1% and 2.4% of BMD, respectively, 
between baseline and 6 months (p=0.071). Standardized BMD (sBMD) at the total hip in 
absolute values (mg/cm²) at baseline and at follow-up are displayed in the figure below 
(Figure 3).  
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There was no change in total body BMD between baseline and 12 months in the BN group, 
while the B group and C group both lost BMD, C more so than B (p=0.009). The findings 
from the intention-to-treat analysis (ITT) were in line with the complete-case analyses, 
showing significant group differences in total hip BMD at 6-month follow-up (p=0.03) and in 
total body BMD at 12-month follow-up (p=0.03).  
 
There was a trend toward differences in serum CTX-I after 12 months (p=0.055) that was 
confirmed by the intention-to treat analysis, which showed a more pronounced decrease 
within the B and BN group compared with the C group (p=0.019). An analysis of intra-group 
changes in serum CTX-I between baseline and 12 months showed a significant decrease in 
the BN and B groups of 36% and 33%, respectively (p <0.001), whereas the C group showed 
a smaller, non-significant decrease of 12% (p=0.77).  
 
A total of 59% (n=47) of all participants had a baseline serum-25OHD below normal (< 50 
nmol/L); 11 of them had values indicating severe deficiency (< 25 nmol/L). At the12-month 
follow-up 26% of patients still had serum-25OHD concentrations < 50 nmol/L. Average 
serum-PTH was within normal range for all groups at inclusion and remained normal during 
follow-ups. There were no significant differences between the three treatment groups in 
serum-25OHD or serum-PTH on any measurement occasion; this result was supported by the 
ITT analyses. 
 
Figure 3 Standardized BMD (sBMD) at the total hip in absolute values (mg/cm²) at 
baseline and at follow-up 
 
Abbreviations: sBMD, standardized bone mineral density; BN: bisphosphonate together 
with nutritional supplementation and calcium + vitamin D; B: bisphosphonate and calcium + 
vitamin D; C: controls treated with calcium + vitamin D 
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4.3 STUDY III 
 
The study population for this study was the same as for study II. Baseline measurements 
showed low FFMI in 22 of 79 (28%) patients and low aLMI in 32 of 79 (40%). A strong 
positive correlation between FFMI and aLMI was found, r=0.92, p <0.01. The total number 
of patients defined as having sarcopenia (both low aLMI and low HGS), was 16 out of 75 
(21%) at baseline; the corresponding figures at 6 and 12 months were 24% and 29%, 
respectively, with no significant difference between groups over the observation period. 
During the first year an overall loss of body mass and FFM were found. Complete-case 
analyses showed a trend toward increased FMI with a pronounced decrease in FFMI and 
aLMI in the N group, shown in the table below. The ITT analyses confirmed this trend, 
showing no loss in FMI at 6 months (p=0.01) and a greater loss of FFMI in the N group 
compared with the other two groups at 6 and 12 months (p <0.001 and p=0.006, 
respectively). A moderate positive correlation was found between aLMI and HGS at baseline 
(rs=0.47, p <0.01), and at 6 (rs=0.61, p <0.01) and 12 months (rs=0.64, p <0.01) 
 
 
 
Table 1 Outcome of body composition components in study III 
  All patients Group N Group B  
 
Group C   
 
 
 Months     p-
value 
Body mass,  
kg (SD), % 
a
0-6 
b
0-12 
-2.1 (3.5), -3.4 
-1.6 (4.0), -2.8 
-2.0 (3.5), -3.7 
-1.8 (3.0), -3.2 
-3.0 (3.8), -4.3 
-2.2 (4.6), -3.0 
-1.2 (3.2) -2.3 
-0.9 (4.1) -2.1 
0.29 
0.69 
FFM, 
kg (SD), % 
a
0-6
 
b
0-12
 
-1.5 (2.5), -3.3 
-1.6 (2.7), -3.5 
-2.4 (2.0), -5.5 
-2.2 (2.5), -5.1 
-1.3 (3.2), -2.6 
-1.4 (3.2), -2.9 
-1.0 (1.9), -2.4 
-1.3 (2.2), -2.9 
0.09 
0.41 
FM, 
Kg (SD), % 
a
0-6 
b
0-12
 
-0.6 (2.9), -2.7 
-0.2 (3.4), -0.2 
+0.4 (2.3), 
+1.0 
+0.4 (2.1), 
+3.1 
-1.7 (3.6), -7.0 
-0.7 (4.4), -0.9 
-0.2 (2.1), -1.2 
-0.1 (3.0), -1.9 
0.06 
0.64 
aLM, 
kg (SD), % 
a
0-6 
b
0-12
 
-0.1 (1.6), -0.3 
-0.2 (1.6), -1.5 
-0.7 (1.4), -3.9 
-0.4 (1.5), -3.1 
+ 0.3 (1.9), +1.8 
-0.02 (2.0), -0.6 
+0.02 (1.4), +0.3 
-0.2 (1.4), -1.2 
0.06 
0.40 
FFMI, 
kg/m² (SD), % 
a
0-6 
b
0-12 
-0.6 (0.9), -3.3 
-0.6 (1.0), -3.5 
-0.9 (0.7), -5.5 
-0.8 (0.9), -5.1 
-0.4 (1.2), -2.6 
-0.5 (1.2), -2.9 
-0.4 (0.8) -2.4 
-0.5 (0.8) -2.9 
0.08 
0.31 
FMI 
kg/m² (SD), % 
a
0-6 
b
0-12 
-0.2 (1.1), -2.7 
-0.1 (1.2), -0.2 
0.1 (0.8), +1.0 
0.1 (0.8), +3.1 
-0.6 (1.4), -7.0 
-0.3 (1.6), -0.9 
-0.1 (0.8) -1.2 
-0.1 (1.1) -1.9 
0.06 
0.62 
aLMI 
kg/m² (SD), % 
a
0-6 
b
0-12
 
 0.0 (0.6), -0.3 
-0.1 (0.6), -1.5 
-0.2 (0.5), -3.9 
-0.2 (0.5), -3.1 
+0.1 (0.7), +1.8 
 0.0 (0.7), -0.6  
 0.0 (0.6), +0.3 
-0.1 (0.5), -1.2 
0.03 
0.30 
Abbreviations: FFM, Fat Free Mass; FM, Fat Mass; aLM, appendicular Lean Mass; FFMI, 
Fat Free Mass Index; FMI, Fat Mass Index; aLMI, appendicular Lean Mass Index 
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Complete-cases analyses showed a trend toward improved HGS in the N group, although this 
was not confirmed by ITT analysis. Intra-group analyses showed a significant increase in 
HGS within the N group between baseline and 6 months (p=0.04), but this change was not 
significant in the other two groups. The EQ-5D index decreased from 0.86 (SD 0.22) at 
baseline to 0.79 (SD 0.21) at 6 months and 0.74 (SD 0.24) at 12 months for all patients, but 
no difference was found between groups at either of the two follow-ups, p=0.57 and p=0.50, 
respectively. Intra-group analysis showed a significant decrease in the EQ-5D index during 
the first year for the C and B groups (p=0.03 and p=0.01, respectively), but not for the N 
group (p=0.22). Average levels of S-IGF-I and age-adjusted SD score were within normal 
range in all groups at baseline and showed no differences between groups on any 
measurement occasion. The increase in S-IGF-I found in all groups between baseline and 6 
months did not differ among them (p=0.39). 
 
4.4 STUDY IV 
 
One hundred of the included patients were living independently on admission and 70% of 
them were discharged to rehabilitation facilities after surgery, while the corresponding figure 
for patients admitted from institutions was 8%. At the 4-month follow-up, 62% were still 
ambulatory, as were 57% at 12 months. Patients who were discharged to rehabilitation 
facilities were more likely to remain ambulatory at both time points; odds ratio (OR) 2.84 (CI 
95%; 1.16-6.90), p=0.02 at 4-months and OR 2.83 (CI 95%; 1.10-7.26), p= 0.03 at 12-
months. Ambulatory function prior to fracture was also associated with preservation of 
ambulatory function on both measurement occasions, while surgical method was not. At the 
4-month follow up, 22% of patients were wheelchair-bound and the corresponding figure for 
the 12-month follow-up was 28%. Discharge to rehabilitation facilities was associated with 
decreased risk of becoming wheelchair-bound; OR 0.26 (CI 95%; 0.08-0.83), p=0.02 at 4-
months. At the 4-month follow-up, major complications, major reoperations and age were 
also significantly associated with being wheelchair-bound, while type of surgical method was 
not (p=0.67). Independent factors related to wheelchair dependence at 12 months included 
only discharge to rehabilitation facilities and major complications. 
 
At the 4-and 12-month follow-ups, 57% and 48% respectively had preserved ADL skills. 
When adjusted for age and sex, the results showed that patients who were discharged to 
rehabilitation facilities were more likely to have preserved ADL skills; OR 4.24 (CI 95%; 
1.61-11.17), p=0.02 at 4 months and OR 5.33 (CI 95%, 1.44-19.65), p=0.01 at 12 months. 
ADL index prior to fracture was also a significant factor for preserved ADL skills. 
 
 
 
 
 23 
 
5 DISCUSSION 
 
The first overall theme of this thesis was to describe the significance of body mass index for 
survival and independent living one year after hip fracture. The second theme was to evaluate 
whether efforts to promote nutrition could benefit BMD, bodyweight, lean mass, strength and 
thereby health-related quality of life. The third theme was to describe potentially modifiable 
factors of importance to regain walking ability and ADL function after hip fracture. 
 
5.1 STUDY I 
 
In this group of hip fracture patients, overweight and obesity were associated with lower risk 
of death and a higher rate of independent living one year post-fracture. Among geriatric 
patients in general, the mortality rate has been considered to be higher in those with 
underweight (defined as BMI ≤20 97 and BMI <22 98) than in those with normal and high 
BMI (>25 kg/m²) 
99
. In line with this assumption, the present study showed a higher one-year 
mortality rate not only among patients with BMI <22, but also among those with BMI 22-26, 
compared with patients with BMI >26. This finding in hip fracture patients has not been 
presented previously, although earlier studies have shown that patients with a BMI ≤20, as 
well as those with a BMI in the lowest quartile, have been reported to be at increased risk for 
mortality 
71,
 
100,
 
23
. Consistent with our findings, a recent study on fracture patients in general, 
aged ≥40 years, showed a reduced risk of death among overweight ( BMI 25-29.9 kg/m²) and 
obese (≥30 kg/m²) individuals compared with those of normal weight (18.5 to < 25 kg/m²)101. 
Similarly, an increased mortality rate has been shown in patients with BMI ≤24 undergoing 
cardiac valvular surgery 
102
, as well as a lower risk of death in obese patients following 
primary shoulder arthroplasty 
103
. A lower risk of mortality among individuals with BMI up 
to 30 kg/m² has also been reported in a cohort study of patients with dementia 
104
. These 
observations have been termed “the obesity paradox” indicating that among the elderly, 
obesity is inversely associated with a lower, not higher, risk of death 
105
. Obesity as a risk 
factor for cardiovascular disease and increased mortality is otherwise a well-established 
paradigm in the adult population at large 
106,
 
107
. Among the suggested explanations for “the 
obesity paradox” in the elderly are competing risk factors, comorbidities and survival bias. 
Another suggested explanation is that obesity in the elderly may have a protective effect 
against oxidative stress and inflammation 
108,
 
109
; however the underlying mechanisms remain 
unclear. The findings in the present study may imply that a larger energy reserve is needed to 
meet the increased metabolic demands associated with trauma and postoperative catabolism 
following hip fracture and surgical procedures in general 
110,111
.  
The age and sex distribution in the present study corresponded well to previous reports 
concerning hip fracture patients, which makes our study population representative 
112,
 
113
. A 
significant number of patients had low BMI, indicating risk of malnutrition, which is in line 
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with earlier reports on patients with hip fracture 
23,
 
24, 114
. The results in the present study 
showed a lower overall one-year mortality of 15% compared with previous studies showing 
22-29% 
115,116
. One possible explanation for this finding was the exclusion of patients with 
severe cognitive impairment and those living in nursing homes. These factors are well known 
to be associated with an increased mortality rate 
11,
 
117,
 
118
.  
Advanced age, sex, comorbidities prior to fracture, pre-fracture level of function, history of 
dementia and living situation (alone or with others) are all factors reported to influence the 
ability to return to independent living following hip fracture 
119
. In contrast to the current 
study, no prior study has shown that overweight and obesity are associated with a higher 
probability of independent living 12 months after a hip fracture. On the other hand, both low 
BMI and weight loss after hip fracture have been associated with weakness and poor function 
in regard to walking speed at 6 months and handgrip strength at 12 months postoperatively 
120
. One earlier report on geriatric patients in general has also shown low BMI and 
underweight to be risk factors for functional decline 
121
. Furthermore, low BMI in non-
disabled but medically ill patients at the time of hospital admission has been reported to 
predict impaired ADL function at the time of discharge 
122
, thereby likely affecting the ability 
to live independently. 
 
Strengths and limitations study I 
BMI was only assessed at inclusion and weight change over time was not recorded, so the 
only conclusion that could be drawn is that BMI at time of fracture was associated with 
outcome after one year. However, earlier studies have shown that weight loss is common 
following hip fracture 
123,
 
120,
 
124
. Furthermore, weight loss along with loss of total lean mass 
and loss of fat mass have been associated with increased mortality among men 65 years or 
older 
125
. Another limitation is that BMI does not provide detailed information on body 
composition, neither on the distribution nor on the ratio between lean and fat mass. 
The prospective design with a large number of consecutively enrolled patients was a major 
strength of this study, while the focus on studying a group of relatively healthy elderly hip 
fracture patients added novelty. 
 
5.2 STUDY II 
                                                                                                                                                               
We found that nutritional supplementation in addition to calcium, vitamin D, and risedronate 
had a beneficial effect on total hip BMD and total body BMD in elderly patients with a recent 
hip fracture. An annual loss of 0.27% and 0.25% of total hip BMD in women and men, 
respectively, has been reported for a healthy population, aged 50-85 years 
126
, but a higher 
protein intake in elderly individuals has been associated with lower bone loss 
127
 and higher 
bone mineral content 
128
. Conflicting with these findings is the hypothesis that high protein 
intake results in increased bone loss due to higher acid load 
129
. According to this line of 
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thinking, high acid load needs to be buffered, which leads to release of calcium together with 
carbonate from the skeletal reservoir through increased osteoclast activity, thereby causing 
increased bone loss 
129
. Yet it has also been reported that increased urinary excretion of 
calcium due to high protein intake had no deleterious effects on calcium retention 
130
. Further 
results from the same study showed an increase of IGF-I, which is generally assumed to have 
anabolic effects on bone mass 
130
. The thinking underlying the present study was to 
compensate an assumed poor intake of protein and the hypothesis was that this would reduce 
loss of bone mass following hip fracture. A trend toward an increase in total hip BMD after 
12 months on a protein-containing supplement has been observed, along with a decrease in 
serum CTX-I, in a study of 71 community-dwelling women with low BMI (≤21 kg/m²) 131. 
Earlier studies have shown a loss of 2.0-4.6% of BMD in the uninjured hip during the first 
year following hip fracture 
39,
 
40,
 which is consistent with the findings in the control group for 
the current study.  
A lower incidence of a second hip fracture has been reported in patients treated with 
risedronate 
132
. Previous studies have also reported an increase in total hip BMD post-hip 
fracture following treatment with parenterally administered bisphosphonate 
63, 133
. The 
present study involved oral administration of bisphosphonate, which could explain the lower 
net gain in BMD compared with the previous study 
63
, since absorption of orally administered 
treatment is low even under ideal circumstances. Another important consideration is the well-
known suboptimal patient compliance with orally administered bisphosphonates 
134,
 
135
, 
which we also observed in the current study. 
A few previous studies have explored the possible effects of protein and energy-rich 
nutritional supplements on BMD following hip fracture. A randomized trial of 60 women 
with hip fracture evaluated the treatment effects of protein-rich supplementation alone or in 
combination with anabolic steroids on both hip and total body BMD 
136
. Although the 
difference in BMD between the groups did not reach statistical significance, the results of that 
study indicated an increase in total body BMD at 6 and 12 months in the groups that received 
protein and energy supplementation, compared with the group treated with calcium and 
vitamin D alone 
136
. Yet another study of 82 hip fracture patients showed that protein 
supplementation (20 grams daily) for 12 months following hip fracture preserved BMD, 
compared with untreated controls 
51
. The nutritional supplementation used in our current 
study provided a 40 g daily dose of protein, compared with only 20 g in the previous studies 
51,
 
136
, which may explain the BMD-preserving effect observed after only six months. 
Furthermore, participants in our study received 600 kcal/day in supplementation, instead of 
the 250 kcal/day in one of the previous studies 
51
. Unlike previous studies, patients in the 
current study were also treated with drugs that inhibit bone resorption 
51,
 
136
. The mean 
change in total hip BMD in the present study did not reach statistical significance, but the 
explanation may lie in the small group sizes. However, the intention-to-treat analysis 
supported the results of complete-case analysis, showing a significant difference between 
groups in total hip BMD at 6 months and total body BMD at 12 months.  
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We found no differences in vitamin D levels between groups to explain the disparities in 
BMD. All patients received vitamin D and the mean values of serum-25OHD were 
normalized in each group during the study period. However, 26% of all included patients still 
had values < 50 nmol/L at the final follow-up, which is consistent with the results from a 
prior study in which hospitalized women aged 66 to 95 were treated with vitamin D3 (800 IE) 
and calcium (1000 mg) 
137
. Possible explanations for why all patients did not normalize their 
25OHD concentration include insufficient vitamin D dose, a short 3-month period of 
supplementation and noncompliance issues 
137
. The first and last of these reasons may also 
apply to the current study.  
 
The decrease in bone resorption marker S-CTX-I levels became more pronounced in both 
risedronate-treated groups at 12 months. Since bone resorption inhibitors decrease CTX 
levels, these results reflect the expected treatment response to risedronate. An earlier study 
concerning the natural course of bone resorption markers following fracture showed an 
increase in the levels within two weeks and the levels remained elevated for up to a year 
compared with pre-fracture levels 
36
. CTX levels vary greatly among individuals. The degree 
of increase post-fracture depends on the size of the fractured bone, but other causes of 
variability include circadian rhythm, food intake and physical activity - factors that the 
present study did not take into account 
34, 37
.  
 
Strengths and limitations study II 
The selection of slightly younger and healthier than average hip fracture patients makes it 
impossible to generalize the results. Group size was also a limiting factor, as was lack of 
compliance despite regular telephone follow-ups. Although the study lasted for one year, the 
nutritional supplementation was only provided during the first 6 postoperative months, when 
the degree of catabolism is likely to be most pronounced.  
The combined treatment with bisphosphonate and nutritional supplementation was novel and 
the randomized design was one of the strengths, as was the relatively long treatment period. 
 
5.3 STUDY III 
 
In this study we found that nutritional supplementation in addition to bisphosphonate, 
calcium and vitamin D produced no additive effect on lean mass, handgrip strength or 
HRQoL compared with either bisphosphonate with calcium and vitamin D, or calcium and 
vitamin D alone. Thus, none of the study hypotheses could be confirmed. The results of the 
intention-to-treat analysis were in line with those of the complete-case analysis. However, 
intra-group analysis did show a beneficial effect on HRQoL, as well as improved HGS in the 
nutritional supplementation group. These intra-group differences may indicate that the study 
was underpowered and therefore unable to answer the questions posed. Post-hoc analyses 
showed that at least 135 patients (vs the 79 in this study) would be needed to reach statistical 
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significance between groups to address effect on HGS. Furthermore, because some studies 
suggest that vitamin D has beneficial effects on muscle strength, the administration of 
vitamin D to all groups may have negated any significant differences in treatment effects 
among groups 
138,
 
139
. However, other studies have failed to show any effect of vitamin D on 
muscle strength 
140,
 
141
. The finding of lean mass loss despite protein-rich nutritional 
supplementation following hip fracture is consistent with a previous study 
142
. Loss of lean 
mass in the prior study was 1.6 kg (SD 1.5) and in the present study 2.1 kg (SD 2.6) during 
the first year post-fracture, despite nutritional supplementation in both studies. The prior 
study showed that lean mass was preserved during the first 6 months only among patients 
who received an anabolic steroid in addition to supplementation 
142
. Loss of lean mass 
following hip fracture has been reported at 5-6 % during the first year 
123,
 
39,
 
40
, which is in 
line with the observed loss of 5.2% in our study, even though our patients received nutritional 
support for 6 months. 
A negative energy balance in response to injury possibly explains the difficulties in 
benefitting from nutritional supplementation, since the metabolic, hormonal and 
inflammatory response to trauma and surgery results in an accelerated and prolonged 
breakdown of muscle protein 
111,
 
143
. Moreover, it is important to keep in mind that many hip 
fracture patients suffer from poor nutrition 
144
 and a negative energy balance already prior to 
hip fracture 
123, 145
. Recently, focus on the composition of protein supplementation has 
increased as indications have emerged that certain essential amino acids, specifically the 
branched-chain amino acid leucine that is abundant in whey protein and its metabolite 
hydroxy-methyl-butyrate (HMB), may have anabolic effects in addition to purely nutritional 
effects 
146,147
. The current study used a traditional balanced mix of proteins. Further studies 
are needed to assess whether more explicit beneficial effects could be obtained using these 
specific protein compounds.  
 
The proportion of patients with sarcopenia did not differ among groups over the observation 
period. The prevalence of sarcopenia was 21% at baseline, and 24% and 29%, respectively 
after 6 and 12 months, which confirms earlier reports of a catabolic state that persists during 
the first year post-hip fracture 
33
. The proportion of hip fracture patients with low aLMI at 
baseline has previously been reported to be 47%, compared with 40% in the present study 
48
. 
This slight difference may be due to differences in the selection of patients as well as to the 
use of different normative data. We found a higher proportion of patients with low aLMI at 
both 6 and 12 months than at baseline, but no previous studies with aLMI results up to one 
year following hip fracture are available for comparison. A trend toward preserved FMI was 
seen at 6 months in the nutritional supplementation group, which was strongly supported by 
the intention-to-treat analysis; similar effects on FMI were shown in a previous study using 
nutritional support prior to elective hip surgery 
148
. A possible explanation for preserved FMI, 
albeit not FFMI, through nutritional supplementation in the present study might be the effect 
that the lack of resistance training during rehabilitation could have on fat metabolism. 
However, exercise programs with resistance training combined with nutritional 
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supplementation have been reported to result in gain of both lean mass and fat mass 
149
.  
 
We found improvement in HGS within the protein and energy supplementation group 
between baseline and 6 months. A similar improvement in HGS after 3 months of nutritional 
supplementation has been shown earlier in elderly patients following hospitalization due to 
acute illness, as well as in chronically-ill outpatients 
150,151
. This is important, since 
sarcopenia is not defined by reduced muscle mass alone, but by the combination of reduced 
muscle mass and reduced muscle strength or physical performance 
41
. The reason for this is 
that function, as indicated by strength and/or physical performance, is a complex parameter 
that relates to more than just muscle mass, and that muscle function may improve, even when 
muscle mass remains unaffected 
152,
 
153,
 
154
. This may help explain our findings in the 
nutritional supplementation group that show a trend toward preserved HGS, but not FFMI, as 
well as the modest relationship between HGS and aLMI found in our analysis. We chose to 
study HGS in the present study since a strong association has been shown between HGS and 
leg muscle strength, and also because HGS actually predicts mobility better than muscle mass 
49,
 
155
. Consistent with these earlier reports on HGS, recent studies showed HGS but not 
appendicular lean mass to be independently associated with functional outcome after hip 
fracture 
154,
 
156
. 
 
HRQoL decreased in all groups and failed to reach pre-fracture levels by 12 months, findings 
consistent with an earlier study following hip fracture 
157
. However, intra-group analysis 
showed less decline in the nutritional supplementation group. Preservation of HRQoL after 
hip fracture has not previously been seen following supplementation alone, but has been 
demonstrated when supplementation was combined with an anabolic steroid 
142
. 
 
Strengths and limitations study III 
As mentioned above, one major limitation is the small number of study subjects, which may 
lead to type 2 errors, i.e. the risk of missing a true positive effect. The difficulties of including 
large numbers of hip fracture patients in intervention studies with nutritional supplementation 
are generally acknowledged 
54
. Other limitations include the high attrition rate and 
suboptimal compliance in the nutritional supplementation group, both of which have been 
encountered in earlier studies 
158,
 
159
. Further, intervention was first initiated postoperatively, 
which may have reduced the ability to counter the effects of the catabolic process already 
underway before surgery. Another limitation was that due to the multicenter design of the 
study, patients were examined by different DXA systems. However, patients were 
randomized to all treatment groups and were measured by the same DXA equipment at all 
three occasions.   
The strength and novelty of this study lie in the DXA measurements of body composition, 
with assessment of changes in fat-free mass, fat mass, appendicular muscle mass, strength 
and HRQoL, for evaluation of the response to oral nutritional supplementation following hip 
fracture in the elderly. Other attributes include assessment of appendicular lean mass index 
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together with HGS to determine the prevalence of sarcopenia in the study population not just 
at baseline, but also postoperatively for one year.  
 
 
5.4 STUDY IV 
 
This study showed that discharge to rehabilitation was associated with preserved ambulatory 
function, ADL skills and less risk of becoming wheelchair-bound in patients with femoral 
neck fracture and cognitive impairment. As shown in previous studies, pre-fracture function 
was also associated with preserved ambulatory and ADL function following fracture 
160,
 
161
.  
 
Rehabilitation is crucial for regaining pre-fracture ambulatory and ADL function following 
hip fracture 
66,
 
162
. A multidisciplinary rehabilitation program has been shown to reduce the 
risk of falls, even for patients with dementia 
163
. Furthermore, previous studies have shown 
that patients with cognitive impairment can regain pre-fracture mobility and ADL function if 
they undergo targeted rehabilitation following hip fracture surgery 
72,
 
164,
 
165,
 
166
. One study 
reported that pre-fracture mobility rather than cognitive level is associated with regaining 
motor function after hip fracture 
160
. Others have shown that the association between 
cognitive impairment and poor functional outcome in patients with hip fracture was actually 
dependent on rehabilitation participation 
167,
 
168
, yet patients with dementia are less likely to 
be admitted to rehabilitation facilities 
169
. 
In the present study, the strongest factor for discharge to rehabilitation was patient's previous 
living situation, also consistent with a previous report 
170
. As in other studies, we found that 
patients who were admitted to a hospital from an institution were seldom considered for 
inpatient rehabilitation after discharge from an acute care hospital 
171
. In general, patients 
admitted from institutions have shorter hospital stays and are discharged from the acute care 
hospital as soon as they are medically stable 
172
. Possible explanations may be the perception 
that these patients fare better in a familiar environment, or that community-based nursing 
homes offer adequate rehabilitation resources, for which reason their patients are not 
considered for rehabilitation in outside facilities. However, the situation may also reflect an 
attempt to increase efficiency 
173
 or a shortage of beds in geriatric rehabilitation facilities. 
Since it is likely that patients admitted from residential care homes are more frail than those 
living independently 
118
, they may benefit from the support of a rehabilitation team to cope 
with their new situation following hip fracture. Nevertheless, it may be reasonable to assume 
that there is a general shortage of rehabilitation resources in community-based nursing 
homes. In line with our findings a prior study showed that those discharged to rehabilitation 
facilities had superior function at 12 and 24 weeks compared with patients in nursing homes, 
even after controlling for important confounders 
174,
 
170
.  
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The present study also showed that about one third of all patients were wheelchair-bound at 
the 12 month follow-up, which is consistent with a previous study 
175
, but we found that 
patients who were discharged to a rehabilitation facility were less likely to become 
wheelchair-bound. Reoperation was also associated with wheelchair use, but only at the 4-
month follow-up.  
Since our study was published, other researchers have obtained similar results that strengthen 
our findings. For example, one study has reported that even patients with moderate to severe 
cognitive impairment can achieve independent ambulation after hip fracture rehabilitation, a 
result that was maintained at one year 
176
. Another recently published study which also 
corroborated our findings showed that pre-fracture motor function, but not cognitive 
impairment (SPMSQ < 3), was associated with preserved ambulatory function and pre-
fracture ADL skills 4 months after fracture 
177
.  
 
Strengths and limitations study IV 
Due to selection of patients with cognitive impairment, all data were collected by proxy 
interviews. No reliability testing of information provided by proxy was undertaken in the 
present study, but previous studies have shown that proxy-patient agreement is reasonably 
accurate for concrete observable variables and moderately reliable for subjective variables 
178,
 
179
. No information relevant to decisions concerning discharge to rehabilitation facilities was 
collected. However, patients discharged to rehabilitation facilities were found to be similar to 
those who were not regarding cognitive function, age, gender, ASA score, fracture type, 
surgical method and ambulatory function prior to fracture. Since cognitive impairment may 
be a manifestation of both dementia and delirium, one methodological issue to be 
acknowledged is that the SPMSQ in the current study made no distinction between these two 
conditions. However, an SPMSQ score of <3 was defined as severe cognitive impairment for 
the purpose of the current study and is known to be associated with poor outcome regarding 
ambulatory function, ADL skills and mortality post-hip fracture, irrespective of whether the 
diagnosis is delirium or dementia 
11,
 
12, 180
.  
The choice of ambulatory function and ADL skills as primary outcome variables was a 
strength of the study since these variables are important for autonomy and health-related 
quality of life 
45
. Another strength of our study was the rather low attrition rate. 
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6 CONCLUSIONS 
 
Overweight and obese patients achieved a better one-year survival rate and were more likely 
to return to independent living than patients with normal or low weight. The addition of 
protein and energy-rich supplementation to orally administered bisphosphonate showed a 
small additive effect on total hip and total body BMD postoperatively in the group of hip 
fracture patients receiving this treatment. However, nutritional supplementation combined 
with conventional rehabilitation did not preserve fat-free mass any better than taking vitamin 
D and calcium alone, or together with bisphosphonate. There were no inter-group differences 
concerning effects on HGS or HRQoL, but intra-group analysis indicated beneficial effects 
on both these outcomes. The study on hip fracture patients with cognitive impairment showed 
that, ambulatory and ADL function prior to hip fracture and discharge to a rehabilitation 
facility were independently associated with preserved ambulatory and ADL function 4 and 12 
months postoperatively. 
 
The findings in the studies, indicate that elderly hip fracture patients may benefit from being 
overweight; however, the underlying mechanisms are unclear and further research is needed. 
Because the aging process itself is associated with decreasing physiological reserves, a low 
BMI on hospital admission may already signal a marginal nutritional status. The findings of 
the association between BMI and both one-year survival and capacity for independent living 
are of importance since body weight is a potentially modifiable factor. The interventional 
study indicates minor beneficial effects on BMD, FM, HGS and HRQoL; further research is 
needed to verify these effects and whether good nutritional status may reduce morbidity, 
mortality and risk of fracture following hip fracture. In the meantime, it would seem 
reasonable to prevent postoperative weight loss, for which reason recommendations for 
optimal BMI need further consideration in this patient group. Lastly, in order for patients 
with hip fracture and cognitive impairment to achieve better functional outcome, it is likely 
important to provide access to rehabilitation. 
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7 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Höftfraktur är ett samlingsnamn för benbrott i övre delen av lårbenet. Bakomliggande 
riskfaktorer för höftfraktur är flera men en av de starkaste är benskörhet s.k. osteoporos som 
kännetecknas av låg bentäthet och ökad risk för benbrott. I Sverige inträffar ca 70 000 
osteoporosrelaterade benbrott varje år varav 18 000 utgörs av höftfrakturer. Medelåldern hos 
de som drabbas av höftfraktur är 82 år och 68 % är kvinnor. Hos personer över 70 år 
uppkommer de flesta höftfrakturerna inomhus genom fall i samma plan. Alla höftfrakturer 
opereras med några få undantag. Höftfraktur är den allvarligaste benskörhetsfrakturen 
eftersom den är förenad med ökad dödlighet. Tidigare forskning har visat att 25-30 % av 
patienterna aldrig kan återvända till eget boende och prognosen är särskilt dålig för patienter 
med nedsatt minnesfunktion eller konstaterad demenssjukdom. 
Vid jämförelse med friska äldre i samma åldersgrupp är det en högre andel av 
höftfrakturpatienterna som är underviktiga dvs de har ett lågt body mass index (BMI). Detta 
kan vara ett tecken på undernäring och lågt BMI är en riskfaktor för osteoporos. Ytterligare 
viktnedgång månaderna efter höftfrakturen är vanlig, förlust av benvävnad och muskelmassa 
i samband med detta har påvisats. Muskelförlust kan vara förenat med svaghet som i sin tur 
kan leda till försämrad funktion och livskvalitet.  
 
Det övergripande syftet med avhandlingen var att studera ett eventuellt samband mellan 
kroppsvikt och prognos efter höftfraktur hos äldre. Vi undersökte också effekterna av 
interventionsbehandling med läkemedel mot benskörhet och extra näringstillförsel efter 
höftfraktur. Dessutom studerades faktorer som hade samband med bibehållen gångförmåga 
och funktion hos patienter med nedsatt minnesfunktion, också det efter höftfraktur. 
 
I studie I ingick 843 patienter över 65 år med höftfraktur. Alla patienter kom från eget 
boende, de var gångare innan frakturen och hade ingen uttalad minnespåverkan. Sambandet 
mellan BMI, 1-års dödlighet och förmågan att återvända till sitt hem ett år efter höftfraktur 
undersöktes. Resultaten visade att övervikt var positivt hos denna specifika grupp av 
patienter. Högt BMI var förenat med en ökad 1-årsöverlevnad och en större sannolikhet att ha 
återvänt till sitt hem ett år efter frakturen. 
 
I studie II ingick 79 män och kvinnor med höftfraktur, som var gångare före frakturen och 
kom från eget boende. Patienterna delades in i tre behandlingsgrupper genom lottning.  Den 
ena gruppen fick ett protein-och energirikt näringstillskott dagligen i 6 månader efter 
frakturen, som tillägg till etablerad läkemedelsbehandling mot benskörhet. Den andra 
gruppen fick benskörhets- behandling och den tredje gruppen utgjorde kontrollgrupp. 
Patienterna följdes upp under ett år och resultaten påvisade en positiv effekt på bentätheten 
hos den grupp av patienter som fått extra näring. 
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I studie III ingick samma patienter som i studie II men här utvärderades effekten av 
behandling med det protein-och energirika näringstillskottet på muskelmassan, handstyrkan 
och den hälsorelaterade livskvaliteten. Resultaten visade att den grupp som fått 
näringstillskott förlorade lika mycket muskelmassa som de övriga två grupperna men en 
antydd positiv effekt på handstyrka och hälsorelaterad livskvalitet påvisades.      
 
I studie IV ingick 246 patienter med höftfraktur och nedsatt minnesfunktion eller 
demenssjukdom. Patienterna följdes upp efter 4 och 12 månader avseende gångförmåga och 
förmågan att klara dagliga basala aktiviteter som till exempel påklädning, toalettbesök och 
födointag. Resultaten visade att vistelse på rehabiliteringsenhet hade ett samband med 
bevarad gångförmåga och för förmågan att klara dagliga aktiviter för denna grupp av 
patienter med nedsatt minnesfunktion. Andra faktorer såsom gång -och funktionsförmåga 
innan skadan hade betydelse för funktionen efter ett år. Dessutom visade resultaten att 
patienter som skrivits ut till rehabiliteringsklinik i mindre utsträckning var rullstolsbundna. 
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